Abstract:Accurate drug response prediction is a critical bottleneck in computational biochemistry, limited by the challenge of modelling the interplay between molecular structure and cellular context. In cancer research, this is acute due to tumour heterogeneity and genomic variability, which hinder the identification of effective therapies. Conventional approaches often fail to capture non-linear relationships between chemical features and biological outcomes across diverse cell lines. To address this, we introduce DPD-Cancer, a deep learning method based on a Graph Attention Transformer (GAT) framework. It is designed for small molecule anti-cancer activity classification and the quantitative prediction of cell-line specific responses, specifically growth inhibition concentration (pGI50). Benchmarked against state-of-the-art methods (pdCSM-cancer, ACLPred, and MLASM), DPD-Cancer demonstrated superior performance, achieving an Area Under ROC Curve (AUC) of up to 0.87 on strictly partitioned NCI60 data and up to 0.98 on ACLPred/MLASM datasets. For pGI50 prediction across 10 cancer types and 73 cell lines, the model achieved Pearson's correlation coefficients of up to 0.72 on independent test sets. These findings confirm that attention-based mechanisms offer significant advantages in extracting meaningful molecular representations, establishing DPD-Cancer as a competitive tool for prioritising drug candidates. Furthermore, DPD-Cancer provides explainability by leveraging the attention mechanism to identify and visualise specific molecular substructures, offering actionable insights for lead optimisation. DPD-Cancer is freely available as a web server at: https://biosig.lab.uq.edu.au/dpd_cancer/.